To find a doctor, call 800-667-5356 or click below:

Find a Doctor

Request an Appointment

left banner
right banner
Smaller Larger

Patent Foramen Ovale

PFO Trial

The Amplatzer PFO Occluder in Patients with Recurrent Cryptogenic Stroke Due to Presumed Paradoxical Embolism Through a Patent Foramen Ovale Who Have Failed Conventional Drug Therapy

Principal Investigator

Roger J. Laham, MD

Co-Investigator

Louis Caplan, MD

Coordinator

Paula Rooney, RN
Phone: 617-632-7484
Email: prooney@bidmc.harvard.edu

Focus: Patients with patent foramen ovale (PFO)

The purpose of the Registry is to allow access to the Amplatzer PFO Occluder in subjects with a patent foramen ovale (PFO) who have already experienced at least two strokes due to presumed embolism (a blood clot blocking a brain artery) through a PFO and who have failed conventional drug therapy.

REDUCE Trial

Gore Helex™ Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke or Imaging-Confirmed TIA in Patients with Patent Foramen Ovale (PFO)

Principal Investigator

Roger J. Laham, MD

Co-Investigators

Louis Caplan, MD
Mary Jane McDonald, RN
Paula Rooney, RN
Cathy Troy, RN

Coordinator

Paula Rooney, RN
Phone: 617-632-7484
Email: prooney@bidmc.harvard.edu

Focus: Patients with patent foramen ovale (PFO)

The purpose of the GORE REDUCE trial is to demonstrate that antiplatelet medical management (Aspirin, Plavix , Coumadin ) plus patent foramen ovale (PFO) closure with the Gore Helex™ Septal Occluder reduces the risk of a recurrent stroke of imaging-confirmed transient ischemic attack (TIA) compared to antiplatelet medical management alone in patients with a PFO and history of stroke of imagine-confirmed TIA.